lorlatinib

Generic Name
lorlatinib
Brand Names
Lorbrena, Lorviqua
Drug Type
Small Molecule
Chemical Formula
C21H19FN6O2
CAS Number
1454846-35-5
Unique Ingredient Identifier
OSP71S83EU
Background

Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, fol...

Indication

Lorlatinib is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). In the EU, it is indicated for the treatment of adult patients with ALK-positive advanced NSCLC not previously treated with an ALK inhibitor, or whose disease has progressed after using either alectinib or ceritinib, or crizotinib and ...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer
Associated Therapies
-
Clinical Trials
Related News

Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Phase 2
Recruiting
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Drug: Lorlatinib
First Posted Date
2020-11-09
Last Posted Date
2024-10-11
Lead Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Target Recruit Count
84
Registration Number
NCT04621188
Locations
🇫🇷

Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France

🇫🇷

Centre Paul Papin, Angers, France

🇫🇷

Angers - CHU, Angers, France

and more 34 locations

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4
Completed
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Drug: Lorlatinib
First Posted Date
2020-09-09
Last Posted Date
2024-12-20
Lead Sponsor
Pfizer
Target Recruit Count
100
Registration Number
NCT04541706
Locations
🇮🇳

Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India

🇮🇳

The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India

🇮🇳

Apex Wellness Hospital, Nashik, Maharashtra, India

and more 9 locations

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4
Completed
Conditions
Carcinoma
Non-Small-Cell Lung
Interventions
Drug: Lorlatinib
First Posted Date
2020-04-24
Last Posted Date
2024-11-11
Lead Sponsor
Pfizer
Target Recruit Count
71
Registration Number
NCT04362072
Locations
🇮🇹

Policlinico "G. Rodolico", Catania, Italy

🇺🇸

UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

University Cancer & Blood Center, Llc, Athens, Georgia, United States

and more 38 locations

Lorlatinib Combinations in Lung Cancer

First Posted Date
2020-03-02
Last Posted Date
2021-03-10
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
96
Registration Number
NCT04292119
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Phase 2
Active, not recruiting
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Lorlatinib
First Posted Date
2019-10-15
Last Posted Date
2024-11-05
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
68
Registration Number
NCT04127110
Locations
🇧🇪

Cliniques Universitaires Saint-Luc, Brussels, Belgium

🇪🇸

Hospital Universitari Son Espases, Palma De Mallorca, Spain

🇬🇧

The Christie NHS Foundation Trust, Manchester, United Kingdom

and more 22 locations

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer

Phase 2
Active, not recruiting
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Drug: Lorlatinib
First Posted Date
2019-10-01
Last Posted Date
2024-10-18
Lead Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Target Recruit Count
23
Registration Number
NCT04111705
Locations
🇫🇷

Caen - CHU Côte de Nacre, Caen, France

🇫🇷

Annecy - CH, Annecy, France

🇫🇷

Colmar - CH, Colmar, France

and more 29 locations

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Lorlatinib
First Posted Date
2019-04-10
Last Posted Date
2024-11-22
Lead Sponsor
Pfizer
Target Recruit Count
109
Registration Number
NCT03909971
Locations
🇨🇳

The first hospital of jilin university, Changchun, Jilin, China

🇨🇳

Tangdu Hospital of Fourth Military Medical University, Xi'an, Shanxi, China

🇨🇳

Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China

and more 18 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

First Posted Date
2018-11-13
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
10
Registration Number
NCT03737994
Locations
🇺🇸

Miller-Dwan Hospital, Duluth, Minnesota, United States

🇺🇸

Fairview Southdale Hospital, Edina, Minnesota, United States

🇺🇸

Grady Memorial Hospital, Delaware, Ohio, United States

and more 487 locations

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1
Terminated
Conditions
Advanced Cancers
Interventions
Drug: lorlatinib
First Posted Date
2018-10-31
Last Posted Date
2024-06-21
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT03726333
Locations
🇺🇸

University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy